Codexis Inc. (CDXS)
2.29
-0.20 (-8.03%)
At close: Apr 03, 2025, 11:51 AM
-8.03% (1D)
| Bid | 2.2 |
| Market Cap | 190.11M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -0.89 |
| PE Ratio (ttm) | -2.58 |
| Forward PE | -7.16 |
| Analyst | Hold |
| Ask | 2.34 |
| Volume | 302,642 |
| Avg. Volume (20D) | 883,475 |
| Open | 2.30 |
| Previous Close | 2.49 |
| Day's Range | 2.23 - 2.37 |
| 52-Week Range | 2.23 - 6.08 |
| Beta | 2.12 |
About CDXS
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, whi...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 22, 2010
Employees 188
Stock Exchange NASDAQ
Ticker Symbol CDXS
Website https://www.codexis.com
Analyst Forecast
According to 2 analyst ratings, the average rating for CDXS stock is "Hold." The 12-month stock price forecast is $11, which is an increase of 379.30% from the latest price.
Stock ForecastsNext Earnings Release
Codexis Inc. is scheduled to release its earnings on May 1, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago
+20.39%
Codexis shares are trading higher after the compan...
Unlock content with
Pro Subscription
1 month ago
-22.65%
Codexis shares are trading lower after the company reported worse-than-expected Q4 financial results.
